NCT07310290Recruiting
Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
PHASES: Prodrome in tHe reAl World: aSsESsing Ubrogepant Acute Use
Source: ClinicalTrials.gov · Last updated 10 Feb 2026
Brief summary (registry, in English)
Migraine is a neurological disease characterized by moderate or severe headaches, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will assess changes in migraine attack severity for adult participants treating with oral ubrogepant across migraine attacks. Ubrogepant is a drug that is approved for the acute treatment of migraine in adults. Approximately 189 participants will be enrolled in approximately 15 sites across the US. Participants will receive ubrogepant as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 13 weeks. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 189 (estimated)
- First submitted
- 16 Dec 2025
- Start date
- 27 Jan 2026
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- AbbVie
- Diseases
- Migraine
- NCT number
- NCT07310290
What you commit to
- Study type: Observational
- Planned participants: 189
- From 27 Jan 2026 to the primary completion date, 31 Mar 2027
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently participating in a concurrent clinical or non-interventional study.
- Concomitant use with a strong Cytochrome P450 3A4 (CYP3A4 ) inhibitor.
Other
- Current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia, status migrainosus or painful cranial neuropathy as defined by ICHD-3
Who the study is looking for
- History of 4 to 10 migraine days per month with moderate to severe headache pain in each month of the 3 months prior to Visit 1
- --a. Participants with a diagnosis of chronic migraine who report having 4 to 10 migraine days per month with moderate to severe headache pain in each month of the 3 months prior to Visit 1 due to concomitant preventive treatment are allowed in the study
- Participant is currently prescribed ubrogepant and has been using ubrogepant for at least 3 months for the acute treatment of migraine in adults, according to the US Food and Drug Administration (FDA)-approved indication
- Adult participants with current clinical diagnosis of migraine or chronic migraine according to International Classification of Headache Disorders (ICHD)-3
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Neurology and Pain Specialty Center /ID# 278508 Coordinator of this site? Confirm its status | Aliso Viejo | United States | Recruiting |
| Tri City Research Center, LLC /ID# 278800 Coordinator of this site? Confirm its status | Grand Island | United States | Recruiting |
| Chicago Headache Center & Research Inst /ID# 272345 Coordinator of this site? Confirm its status | Naperville | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.